Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages

Roesel, Christian; Terjung, Sarah; Weinreich, Gerhard; Hager, Thomas; Chalvatzoulis, Eleftherios; Metzenmacher, Martin; Welter, Stefan

doi:10.1093/icvts/ivw392

Cited by 31 publications

(43 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 Spindle cell carcinoma is a rare subclassification of sarcomatoid carcinoma. 10 Moreover, sarcomatoid carcinoma only accounts for ∼0.1% to 0.4% of all non–small-cell lung cancer cases. 10 In a thorough review of the reported data, we did not find any recent reports of a diagnosis of spindle cell lung carcinoma after an acute mesenteric ischemic event.…”

Section: Discussionmentioning

confidence: 99%

Acute mesenteric ischemia leading to diagnosis of advanced spindle cell carcinoma of the lung

Mordhorst

Baxter

2020

Journal of Vascular Surgery Cases, Innovations and Techniques

View full text Add to dashboard Cite

Acute ischemic events secondary to pulmonary malignancy are rare. Those who present with acute peripheral arterial occlusions from malignant sources will typically have advanced pulmonary malignancy or myxomatous tumors. A 79-year-old woman had presented to Vancouver General Hospital with acute mesenteric ischemia. The pathology reports after embolectomy indicated cell morphology consistent with spindle cell carcinoma of the lung. Imaging investigations revealed a right upper lobe mass not present on chest imaging studies performed 14 months previously. The findings from the present report serves to remind us that acute ischemic events in the setting of no known history of malignancy or cardiac disease should prompt investigations into possible malignant sources.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute mesenteric ischemia leading to diagnosis of advanced spindle cell carcinoma of the lung

Mordhorst

Baxter

2020

Journal of Vascular Surgery Cases, Innovations and Techniques

View full text Add to dashboard Cite

show abstract

“…PSC are a group of rare and aggressive tumors, which are extremely challenging both to diagnose and to treat 11 .…”

Section: Discussionmentioning

confidence: 99%

“…Although sharing some driver mutations, compared with other NSCLC types, patients with PSC have a more aggressive clinical course and a poorer prognosis, even at earlier tumor stages, with a median survival of 9–12 months in patients with complete tumor resection 11 . PSC patients usually show an unsatisfying response to systemic chemotherapeutical drugs and, currently, there are no efficient therapies 11 .…”

Section: Introductionmentioning

confidence: 99%

Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas

Alì

Bruno

Poma

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Pulmonary sarcomatoid carcinomas (PSC) are a rare group of lung cancer with a median overall survival of 9–12 months. PSC are divided into five histotypes, challenging to diagnose and treat. The identification of PSC biomarkers is warranted, but PSC molecular profile remains to be defined. Herein, a targeted whole transcriptome analysis was performed on 14 PSC samples, evaluated also for the presence of the main oncogene mutations and rearrangements. PSC expression data were compared with transcriptome data of lung adenocarcinomas (LUAD) and squamous cell carcinomas (LUSC) from The Cancer Genome Atlas. Deregulated genes were used for pathway enrichment analysis; the most representative genes were tested by immunohistochemistry (IHC) in an independent cohort (30 PSC, 31 LUAD, 31 LUSC). All PSC cases were investigated for PD-L1 expression. Thirty-eight genes deregulated in PSC were identified, among these IGJ and SLMAP were confirmed by IHC. Moreover, Forkhead box signaling and Fanconi anemia pathways were specifically enriched in PSC. Finally, some PSC harboured alterations in genes targetable by tyrosine kinase inhibitors, as EGFR and MET . We provide a deep molecular characterization of PSC; the identification of specific molecular profiles, besides increasing our knowledge on PSC biology, might suggest new strategies to improve patients management.

show abstract

“…In this study, we reported a case of sarcomatoid carcinoma occurring in the lung. Compared to other types of lung cancer, pulmonary sarcomatoid carcinoma has a worse overall survival [ 15 ]. Pulmonary sarcomatoid carcinoma is characterized by frequent gene mutations.…”

Section: Discussionmentioning

confidence: 99%

Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review

Zhu

et al. 2018

Oncotarget

View full text Add to dashboard Cite

Sarcomatoid carcinoma is a rare malignancy characterized by a combination of epithelial and sarcoma or sarcoma-like components. In this study, we reported one case of pulmonary sarcomatoid carcinoma and evaluated the safety and efficacy of apatinib, a tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptor 2, in treating this disease. The tumor mass was detected in the left lung of a 75-year-old man and showed positive immunostaining for cytokeratin (CK) 7, CK8, smooth muscle actin, CD31, and CD34. Next-generation sequencing analysis identified 4 mutations in NF1 (p.Q347Sfs*29), CDKN2A (p.G23V), ERBB3 (p.V104L), and TP53 (p.V157F) genes. The patient was given apatinib (250 mg) orally once per day. Sustained tumor regression was observed after apatinib treatment. There was no sever complication associated with apatinib therapy. In conclusion, apatinib-based targeted therapy may represent an important option for patients with sarcomatoid carcinoma.

show abstract

Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages

Abstract: Surgical treatment can achieve satisfactory results with low perioperative mortality, but the overall prognosis even with multimodality concepts and in earlier tumour stages is worse compared to other types of non-small cell lung cancer.

Cited by 31 publications

References 29 publications

Acute mesenteric ischemia leading to diagnosis of advanced spindle cell carcinoma of the lung

Acute mesenteric ischemia leading to diagnosis of advanced spindle cell carcinoma of the lung

Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas

Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review

Contact Info

Product

Resources

About